Selective delivery of rifampicin incorporated into poly(dl-lactic-co-glycolic) acid microspheres after phagocytotic uptake by alveolar macrophages, and the killing effect against intracellular Mycobacterium bovis Calmette–Guérin

Yoshida, Aya; Matumoto, Makoto; Hshizume, Hiroyuki; Oba, Yoshiro; Tomishige, Tatuo; Inagawa, Hiroyuki; Kohchi, Chie; Hino, Mami; Ito, Fuminori; Tomoda, Keishiro; Nakajima, Taro; Makino, Kimiko; Terada, Hiroshi; Hori, Hitoshi; Soma, Gen‐Ichiro

doi:10.1016/j.micinf.2006.06.004

Cited by 54 publications

(36 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The increased intracellular CFU inhibitory effect of GP-Rif-Alg compared to free Rif treatment at a sub-MIC concentration of Rif demonstrates the value of GP targeted delivery of Rif to macrophages. Other drug delivery systems for Rif, i.e., PLGA microparticles [2,3], have shown a similar effect in vitro to GP-Rif. PLGA microparticles containing 0.16-0.5 pg Rif/microparticle have shown CFU reduction of ~1.3 log CFU units.…”

Section: Resultsmentioning

confidence: 89%

“…This approach also has the potential to reduce antibiotic resistance and Rif adverse effects, such as hepatotoxicity. New drug delivery methods that have been evaluated with Rif include; liposomes [1], PLGA microparticles [2,3], nanoparticles [4], and dendrimers [5]. These systems have been shown effective for enhancement of drug delivery to macrophages in vitro, but an improved method for effective in vivo delivery of Rif has yet to be found.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Glucan Particle Encapsulated Rifampicin for Targeted Delivery to Macrophages

et al. 2010

View full text Add to dashboard Cite

Glucan particles (GPs) are 2-4 m spherical, hollow, porous shells extracted from Baker's yeast, Saccharomyces cerevisae. The surface of the GPs is composed primarily of 1,3--glucan and the particles are efficiently phagocytosed via receptor-mediated cell uptake by macrophages, phagocytic cells expressing glucan receptors. The hollow cavity of the GPs allows for efficient absorption and encapsulation of payload molecules. Rifampicin (Rif), a drug used in tuberculosis treatment, was encapsulated by precipitation in GPs and trapped using a calcium alginate or chitosan hydrogel to seal the pores of GPs and slow Rif release. Unplugged GP formulations immediately released Rif following particle resuspension in aqueous buffer. Alginate and chitosan sealing of GPs loaded with Rif was able to extend drug release for 24-72 h. GP-Rif formulations containing 10% w/w Rif/GP plugged with a calcium alginate hydrogel were effective at reducing colony forming units of M. tuberculosis strain mc 2 6020 in infected bone marrow macrophages ~80-90% at 24 and 72 hours. The amount of Rif delivered in the GP formulations was below the free Rif minimal inhibitory concentration demonstrating that GP targeted Rif delivery to macrophages enhances Rif antimicrobial effects. OPEN ACCESSPolymers 2010, 2 682

show abstract

Section: Resultsmentioning

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Glucan Particle Encapsulated Rifampicin for Targeted Delivery to Macrophages

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Various studies have been reported where particle uptake was observed in vitro (Yoshida et al, 2006;Kisich et al, 2007). However, this specific study presents data illustrating in vivo particle uptake, by macrophage cells of the peritoneal exudates cells.…”

Section: In Vivo Particle Uptakementioning

confidence: 86%

In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles

Semete

Booysen

Kalombo

et al. 2010

Toxicology and Applied Pharmacology

View full text Add to dashboard Cite

a b s t r a c t a r t i c l e i n f oNanoparticulate drug delivery systems offer great promise in addressing challenges of drug toxicity, poor bioavailability and non-specificity for a number of drugs. Much progress has been reported for nano drug delivery systems for intravenous administration, however very little is known about the effects of orally administered nanoparticles. Furthermore, the development of nanoparticulate systems necessitates a thorough understanding of the biological response post exposure. This study aimed to elucidate the in vivo uptake of chitosan and polyethylene glycol (PEG) coated Poly, DL, lactic-co-glycolic Acid (PLGA) nanoparticles and the immunological response within 24 h of oral and peritoneal administration. These PLGA nanoparticles were administered orally and peritoneally to female Balb/C mice, they were taken up by macrophages of the peritoneum. When these particles were fluorescently labelled, intracellular localisation was observed. The expression of pro-inflammatory cytokines IL-2, IL-6, IL-12p70 and TNF-α in plasma and peritoneal lavage was found to remain at low concentration in PLGA nanoparticles treated mice as well as ZnO nanoparticles during the 24 hour period. However, these were significantly increased in lipopolysaccharide (LPS) treated mice. Of these pro-inflammatory cytokines, IL-6 and IL-12p70 were produced at the highest concentration in the positive control group. The anti-inflammatory cytokines IL-10 and chemokines INF-γ, IL-4, IL-5 remained at normal levels in PLGA treated mice. IL-10 and INF-γ were significantly increased in LPS treated mice. MCP-1 was found to be significantly produced in all groups in the first hours, except the saline treated mice. These results provide the first report to detail the induction of cytokine production by PLGA nanoparticles engineered for oral applications.

show abstract

“…Inhalation of PLGA MS containing the antitubercular agent rifabutin increases the drug residence time in the lungs to more than that by intravenous administration in mice due to uptake of the particles by alveolar phagocytic cells [91]. However, the bacterial population in the rat lung is not significantly decreased by pulmonary administration of RFP-PLGA MS, though granuloma formation on the surface of the lung is reduced [92].…”

Section: Endocytosis-mediated Drug Actionmentioning

confidence: 99%